Generics Lawsuit Is a Problem for All Health-Care Stocks
- The Wall Street Journal
Fresh legal trouble for generic-drug companies underscores bad incentives that characterize the U.S. health-care system.
The sector, which has badly underperformed the market for years, sold off sharply once again on Monday. An amended civil antitrust complaint by more than 40 state attorneys general alleges that 15 individuals and 20 corporate defendants conspired to fix prices of more than 100 generic drugs. Teva Pharmaceutical Industries fell nearly 15% on Monday, while Mylan and Lannett were down 9% and 19%, respectively....